Abstract

Merit Medical Systems, Inc. will release its first-quarter 2026 results on April 30, 2026, Post Market, with investors watching revenue normalization and margin progress following an above-consensus fourth quarter and multiple product and portfolio updates earlier this year.

Market Forecast

Consensus tracked in the finance dataset points to first-quarter revenue of 377.63 million US dollars, up 7.11% year over year, EBIT of 67.89 million US dollars (up 14.10% year over year), and adjusted EPS of 0.83 (up 11.16% year over year). No official gross-margin or net-margin guidance was captured in the current-quarter forecast dataset; the focus is on continued earnings leverage and cost discipline to sustain recent margin gains. Cardiovascular remains the core revenue engine, carrying forward steady procedure volumes and distribution tailwinds into the quarter; it is expected to anchor the projected 7.11% year-over-year top-line growth. Endoscopy appears the most promising near-term growth contributor, underpinned by the March launch of the Resilience Through-the-Scope Esophageal Stent and new tissue-marking capabilities gained from the April acquisition of View Point Medical; last quarter the segment generated 18.94 million US dollars and is positioned to contribute to the company’s 7.11% revenue growth outlook.

Last Quarter Review

Merit Medical Systems, Inc. reported fourth-quarter 2025 revenue of 393.94 million US dollars, gross profit margin of 49.59%, GAAP net profit attributable to the parent company of 38.01 million US dollars, net profit margin of 9.65%, and adjusted EPS of 1.04, up 11.83% year over year. Net profit increased by 36.93% quarter on quarter, supported by operating efficiency and pricing/mix improvements. The Cardiovascular segment generated approximately 375.00 million US dollars and Endoscopy contributed 18.94 million US dollars; company-level revenue increased 10.92% year over year, with Cardiovascular driving the majority of growth.

Current Quarter Outlook

Cardiovascular: Core Revenue Driver

Cardiovascular continues to be the company’s primary revenue contributor, representing about 95.19% of last quarter’s sales, or approximately 375.00 million US dollars. Into the first quarter, the company’s forecast indicates 377.63 million US dollars of total revenue, implying 7.11% year-over-year growth, and the bulk of that uplift is expected to come from Cardiovascular product lines. Distribution and commercial alignment initiatives appear to be reinforcing access and account coverage, which should support stable procedure volumes and consumable demand. With EBIT forecast to grow 14.10% year over year, the quarter points to earnings leverage that often correlates with mix benefits in high-volume Cardiovascular consumables and an ongoing focus on cost control. Pricing remains a watch item; however, the fourth quarter’s 49.59% gross margin and 9.65% net profit margin provide a base from which the company can pursue incremental efficiencies. If inventory normalization at customers remains orderly, the quarter offers a path for sustained gross margin resilience and improved drop-through to EPS.

Endoscopy and Interventional Oncology: Emerging Growth Platforms

Endoscopy contributed 18.94 million US dollars last quarter and is positioned to benefit from product-cycle momentum in the current quarter. On March 16, 2026, the company announced the launch of the Resilience Through-the-Scope Esophageal Stent, which expands its therapeutic toolkit with features designed to enhance control and reduce migration risk. In parallel, on April 01, 2026, Merit Medical Systems closed the acquisition of View Point Medical (approximately 140.00 million US dollars total consideration including assumed liabilities), bringing the OneMark Detection Imaging System and OneMark tissue markers into the portfolio. These assets strengthen the company’s presence in precision localization and post-biopsy/tissue-marking workflows, which can lift attachment rates and pull-through of related disposables. Integration milestones will matter for near-term traction; smooth onboarding and early cross-selling could help Endoscopy outpace the company’s overall 7.11% revenue growth outlook for the quarter. Given the modest base (4.81% of last quarter’s revenue), even incremental wins can meaningfully expand segment growth rates and support consolidated EBIT upside if mix shifts toward higher-value interventional kits and accessories.

Key Stock-Price Drivers This Quarter

Guidance tone and visibility around margins will be a primary driver of post-print sentiment. The company’s last quarter delivered a 36.93% quarter-on-quarter increase in net profit, and investors will look for evidence that cost actions and product mix can sustain earnings leverage; explicit commentary on gross margin versus the fourth quarter’s 49.59% level will be closely parsed. Execution updates tied to the Medtronic distribution agreement announced on March 24, 2026 for ViaVerte (a treatment system for chronic lower-back pain) could be another catalyst; investors will look for signs of revenue contribution and broader partnership synergies within interventional pain management and adjacent channels. Finally, portfolio expansion and integration progress following the View Point Medical acquisition will likely influence the multiple, as investors typically reward clear integration roadmaps, early revenue synergies, and disciplined allocation. Any variance versus the forecasted 377.63 million US dollars of revenue and 0.83 adjusted EPS will compound these factors in shaping the immediate reaction, with particular sensitivity to whether EBIT lands in line with the 67.89 million US dollars expectation and whether management reiterates or raises full-year targets.

Analyst Opinions

Bullish views dominate recent commentary, accounting for the clear majority of tracked opinions; notable firms have reiterated or initiated constructive stances with supportive price targets and margin-expansion narratives. Needham maintained a Buy rating and adjusted its price target to 101.00 US dollars on February 25, 2026, highlighting a strong fourth-quarter beat, an upbeat 2026 outlook, and continued margin expansion. Piper Sandler reiterated Buy, citing sustained operating progress, with recent notes referencing targets of 96.00 US dollars and previously 109.00 US dollars across the last six months; the analyst emphasis centers on execution consistency and earnings quality. BTIG initiated coverage with a Buy rating and a 107.00 US dollars target on February 06, 2026, pointing to product-cycle catalysts and durable revenue drivers that support above-market growth. Canaccord Genuity reaffirmed Buy with a 93.00 US dollars target, arguing that operating momentum and governance stability underpin continued confidence in earnings delivery. Barrington maintained an Outperform rating and trimmed its target to 107.00 US dollars on April 20, 2026, framing near-term upside in the context of conservative expectations and healthy procedural demand. The majority view coalesces around three themes: first, the forecasted 7.11% year-over-year revenue growth and 11.16% adjusted EPS growth for the first quarter are viewed as achievable based on fourth-quarter exit rates and a broader set of commercial actions; second, EBIT growth of 14.10% year over year reinforces the case for sustained margin improvement, which several analysts expect to carry into the midyear timeframe; third, recent portfolio actions, including the acquisition of View Point Medical and the launch of the Resilience esophageal stent, are expected to enhance cross-sell and drive incremental contribution from Endoscopy and interventional oncology adjacencies. In aggregate, these inputs support a constructive stance into April 30, 2026, with attention centered on how management frames second-quarter growth and full-year profitability pathways.